For the year ending 2025-12-31, MDCX had $4,540,895 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss for the year | -35,444,361 |
| Stock-based compensation expense | 1,512,194 |
| Paid-in-kind interest | 429,061 |
| Represents the amount of operating lease right-of-use assets | 97,838 |
| Represents the amount of change in fair value of debentures | 583,823 |
| Repayment of debentures on extinguishment | -25,000 |
| Research and development expense (excluding acquired in process cost) | 8,717,475 |
| Foreign exchange gain/loss | -41,947 |
| Represents the amount of gain loss on settlements | -278,854 |
| Represents the amount of increase decrease in costs related to settlements | 300,000 |
| Represents the amount of costs to issue debentures | 111,725 |
| Prepaid expenses | -352,825 |
| Deferred financing costs | 99,305 |
| Increase (decrease) in accounts payable, trade | 923,552 |
| Increase (decrease) in accounts payable and accrued liabilities | -438,802 |
| Increase (decrease) in operating lease liability | -142,612 |
| Increase (decrease) in accounts payable, related parties | -25,983 |
| Net cash used in operating activities | -22,776,769 |
| Proceeds from convertible debt | 0 |
| Proceeds from issuance initial public offering | 0 |
| Proceeds from issuance of common stock | 9,790,015 |
| Proceeds from issuance of debentures | 11,866,293 |
| Repayment of new debenture | 7,391,107 |
| Represents the amount of proceeds from issuance of shares under settlements | 8,427,416 |
| Proceeds from warrant exercises | 9,874,998 |
| Proceeds from stock options exercised | 162,400 |
| Costs to issue debentures | 136,726 |
| Issuance costs for common shares | 653,504 |
| Net cash provided by financing activities | 31,939,785 |
| Represents the amount of net cash paid for antev asset acquisition including transaction costs | 4,619,152 |
| Cash provided by (used in) investing activity, including discontinued operation | -4,619,152 |
| Effect of exchange rate on cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | -2,969 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation | 4,540,895 |
| Cash and cash equivalents, end of the year | 4,164,323 |
| Cash and cash equivalents, end of the year | 8,705,218 |
Medicus Pharma Ltd. (MDCX)
Medicus Pharma Ltd. (MDCX)